Company intelligence / Profile preview

Molecule to Medicine

Abingdon/Oxford, Oxfordshire, United Kingdommoleculetomedicine.com ↗

Ownership: Private
Development stage: Phase 1

Overview

MTM is not itself developing drugs but has enabled the launch of at least five investment-backed biotech startups with over $205 million in venture capital raised. Its ecosystem accelerates drug discovery and development through integrated support services and advanced informatics platforms. Portfolio company Grey Wolf Therapeutics reached Series B funding ($49M) for its neoantigen creation approach in oncology. Clinical results are reported by portfolio companies rather than MTM directly.

Modalities: Small moleculeBiologic
Industry: Investors

Drug pipeline

1 asset

GRWD5769

Phase 1

Indications: Advanced solid tumors

Beyond the preview

Go deeper on Molecule to Medicine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Molecule to Medicine.

Explore the full profile